Document is current

Article History

Accepted: 2 June 2025

First Online: 23 June 2025

Declarations

:

: This study was funded by AstraZeneca.

: YJ, YY, WZ, YZ, PB, MJ, RCP, and PBL are employees of, and may hold stock in, AstraZeneca. JD was an employee of, and may hold stock in, AstraZeneca. BG and MS were employees of IntiQuan A.G. at the time of the analysis and received funding from AstraZeneca to conduct the modeling and simulation analyses.

: Prior to the initiation of the 12 clinical studies, local institutional review boards reviewed the study protocols and patient consent documents and provided written approvals. All clinical studies were in accordance with the ethical standards of the institutional and/or national research committee, were conducted in accordance with the principles of the Declaration of Helsinki, and were consistent with the International Conference on Harmonization Guidance for Good Clinical Practice and applicable regulatory requirements.

: Not applicable

: Not applicable.

: Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at . Data for studies directly listed on Vivli can be requested through Vivli at . Data for studies not listed on Vivli could be requested through Vivli at . The AstraZeneca Vivli member page also outlines further details: .

: Not applicable.

: All authors contributed to the study design and data interpretation, drafted the manuscript, or revised it critically for important intellectual content, and agree to be accountable for all aspects of the work. All authors read and approved the final manuscript.